Buy Semax Nasal Spray: The Certificate Stops at the Powder

Readers who set out to buy Semax nasal spray are usually choosing between two objects without being told they are two objects: a sealed vial of lyophilised powder, and a solution sitting in a metering bottle. The supplier below sells the first and not the second, which is worth stating plainly at the top rather than at the bottom.

The choice is more consequential than a packaging preference, because the format decides which questions a certificate of analysis can answer at all. A powder report and a spray report are not stronger and weaker versions of one document. They cover different risks, and the risks a spray introduces are the ones least often documented anywhere.

The vial format, and the batch report published for it:

What you are choosing between when you buy Semax nasal spray

A lyophilised vial contains dry peptide under a stopper, freeze dried to remove the water that drives most degradation. It is a raw material presentation: nothing has been diluted, nothing has been preserved, and the container has not been opened since it was sealed. Whatever the laboratory measured is what remains inside until someone breaks the seal.

A nasal spray is a solution plus a device. Peptide has been dissolved in a vehicle at some concentration, a pump has been fitted, and the product is designed to be opened repeatedly over weeks. Each of those steps introduces a variable the powder never had: the concentration in solution, the stability of the peptide once wet, the microbiological state of a container that is opened and closed, and the mechanical consistency of the metering pump itself.

None of that makes the spray a worse object in principle. Delivered-dose uniformity and preservative effectiveness are solvable engineering problems, and licensed nasal products solve them routinely. The difficulty is evidentiary: the consumer sprays sold in this market rarely publish anything about them, while a vial from a research supplier increasingly does publish a batch analysis of its contents. You are not usually choosing between a tested spray and a tested vial. You are choosing between a documented substance and an undocumented product.

What a batch report covers, and exactly where it stops

The certificate published for batch 30-05260628 of the vial format runs to four pages under report number KVR-2026-E848E0, issued by Kovera Labs. It states the sample condition as lyophilised powder at the top of every section, which is the detail that defines its scope.

• Purity 99.886 percent against a specification above 98 percent, by reversed-phase chromatography on a C18 column with diode-array detection at 214 nm. This is the measurement that addresses peptide-related impurities, meaning truncated and modified sequences left over from synthesis.
• Identity by liquid chromatography with mass spectrometry, which asks whether the material is the compound named on the label rather than how clean it is.
• Net content 11.23 mg against an approximate 10 mg specification, so the quantity in the container was weighed rather than assumed.
• Bacterial endotoxin below 0.20 EU/mL against a 0.5 EU/mL acceptance limit, by kinetic chromogenic LAL assay to USP Chapter 85, run against an E. coli O111:B4 standard over a 0.01 to 1.0 EU/mL detection range, across a 2.0 mL dilution volume, which is below 0.40 EU in total for the vial. Endotoxin is a heat-stable fragment of gram-negative bacterial cell wall that survives sterilisation and is invisible in a chromatogram, which is why FDA treats pyrogen testing as a separate discipline.
• Rapid sterility screen: no growth over a two-day incubation at 30 to 35 degrees Celsius, with fungi and yeast not detected. The document notes that full compendial sterility testing under USP Chapter 71 may be required for regulatory purposes, a qualification most vendor paperwork omits.

Every one of those results describes sealed dry powder at a point in time. The endotoxin determination was made in laboratory reagent water, not in a vehicle. The sterility screen was run on material reconstituted by the analyst under controlled conditions, not on a bottle that will be opened repeatedly. The certificate is unusually complete for what it covers, and it covers the substance rather than any preparation made from it.

The questions a spray raises that a powder assay cannot reach

FDA's chemistry guidance for nasal spray and inhalation solution products sets out the controls a licensed product of that type is expected to demonstrate. Reading it against a powder certificate makes the boundary obvious.

The right conclusion is not that sprays are bad and vials are good. It is that the column on the right is a real list of questions, and a consumer spray that publishes no batch document has not answered the left column either. When a spray listing offers a batch code with no corresponding analysis behind it, the code is a stock-control number rather than evidence. The same format problem on the neighbouring compound is worked through in our comparison of spray and vial formats for Selank, where the vendor certificate happens to be thinner than this one.

Why the consumer format became a spray

The published work on this peptide is overwhelmingly intranasal. The 2006 study by Dolotov and colleagues, which reported specific binding in rat basal forebrain and increased brain-derived neurotrophic factor after intranasal application, is representative of a literature in which the nose is the standard route. Consumer sellers followed the literature, and a metering bottle is an easier retail object than a vial of powder: it looks finished, it needs no handling, and it can be photographed.

Route is not a cosmetic detail in the regulatory record either. FDA's published concern is phrased as a risk of immunogenicity for certain routes of administration, arising from the potential for aggregation and peptide-related impurities, with the agency stating it has no or limited safety information for the proposed routes and therefore lacks sufficient information to know whether the drug would cause harm in humans. Aggregation is a physical state a peptide adopts in solution, not in dry powder, which is one more reason the format question and the safety question are the same question wearing different clothes. How route shapes what actually reaches circulation is covered in our guide to peptide bioavailability across routes.

What neither format settles

This is a synthetic seven-residue peptide, PubChem CID 9811102, formula C37H51N9O10S, molecular weight 813.9: the ACTH(4-7) fragment Met-Glu-His-Phe with a Pro-Gly-Pro tail that slows enzymatic breakdown. The literature often calls it an analogue of ACTH(4-10), which describes the same molecule from the other direction, since the final three residues of that fragment are replaced by the tail. It carries a Russian registration, which is a fact about a foreign regulatory system rather than evidence by Western standards, and it holds no FDA marketing authorisation in any presentation. Its nomination for the compounding bulks list was withdrawn by the nominator, so no US pharmacy route exists for a compounded spray either.

A complete certificate is a real advantage and a narrow one: it tells you what was in a container of powder on a particular date. It does not make a compound approved, and it does not answer a question about a device it never examined. Where sterility genuinely is the governing standard rather than an optional extra, the reasoning is set out in our look at sterility claims on an injectable presentation. Nothing on this page describes preparation, handling or use, and there are no quantities here, because that is not what a format comparison is for.